Company intelligence / Profile preview

Novacyte Therapeutics

Beijing, Beijing Shi, Chinanovacyt.com ↗

Ownership: Private
Development stage: Commercial

Overview

Novacyte Therapeutics develops antibody-drug conjugates targeting oncology indications. Its lead asset, NC18, targets HER2 and tubulin and entered Phase 1 trials for HER2-positive or expressing advanced solid tumors. A second program, NC19, targets tubulin and tissue factor for colorectal cancer and remains preclinical. No published clinical results yet; Phase 1 trial recruitment ongoing as of January 2025.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Drug pipeline

1 asset

NC18

Beyond the preview

Go deeper on Novacyte Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novacyte Therapeutics.